STAT

Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is also the author of the morning Pharmalittle newsletter ...
STAT

Massachusetts sues UnitedHealth, alleging fraud in state’s Medicaid plans for seniors

Massachusetts Attorney General Andrea Joy Campbell is suing UnitedHealth Group’s insurance subsidiary, UnitedHealthcare, alleging the company intentionally made low-income older adults appear sicker ...
STAT

At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
STAT

The woman behind the world’s biggest longevity competition

Jamie Justice of XPRIZE Healthspan on the most promising research and "purely scammy" treatments in the world of longevity.
STAT

Trump administration seeks to overhaul federal grantmaking process, alarming researchers

Anil Oza is a general assignment reporter at STAT focused on the NIH and health equity. You can reach him on Signal at aniloza.16. The Trump administration has released a sweeping proposal to overhaul ...
STAT

Which vaccines will curb the Ebola outbreak? WHO debates

As Ebola outbreak grows, the U.S. retreats from the global health leadership. Any Americans who contract Ebola will not be brought to the United States for treatment, Trump admini ...
STAT

Trump, questioning vaccine safety, pushes major changes to how kids get shots

Daniel covers the intersection of the health industry and the federal government. He reports on corporate influence in government, the health consequences of federal policies, and the politics of ...
STAT

Up and down the ladder: The latest comings and goings

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is also the author of the morning Pharmalittle newsletter ...
STAT

Biotech exec Jeremy Levin on the industry’s strategic turning point

This week on "The Readout LOUD," longtime biotech exec Jeremy Levin talks about his new book and the industry's strategic turning point. Listen now.
STAT

Pharmalittle: We’re reading about biotech investors’ mood, a former FDA head’s confidence, and more

For Wall Street, the political risk of investing in drug companies has been demoted in comparison to other concerns ...
STAT

Blood pressure tech floods the market after FDA relaxes wearables oversight

Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech; the use of AI in clinical care; mental health chatbots; and consumer ...
STAT

‘Are we just going to give up and die like every other generation?’

Inside the longevity conference that brings together founders, investors, biohackers, and the generally death-averse to ...